DDInter1398 DDInter1376
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pasireotide {u} (Compound) resembles {v} (Compound) Terlipressin
Pasireotide {u} (Compound) binds {v} (Gene) SSTR5
Pasireotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Pasireotide {u} (Compound) causes {v} (Side Effect) Abdominal pain
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pasireotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoprolol
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Protriptyline
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Pasireotide (Compound) resembles Terlipressin (Compound)
Pasireotide (Compound) binds SSTR5 (Gene)
Pasireotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Pasireotide (Compound) causes Abdominal pain (Side Effect)
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol
Pasireotide may lead to a major life threatening interaction when taken with Protriptyline
Pasireotide may lead to a major life threatening interaction when taken with Fingolimod